


Injectable hydrogels for ocular drug delivery: antibodies and corticosteroids

In recent years, there has been considerable interest in the development of injectable hydrogels for drug delivery applications. These hydrogels offer controlled release of therapeutic agents at specific locations in the body. In order to render hydrogel materials injectable, their composition needs to be carefully designed to enable transitioning from a solution to a gel in response to certain stimuli such as a change in temperature or pH.

This lecture will discuss the design of injectable hydrogels for the delivery of proteins and low molecular weight therapeutics aimed for local treatment of ocular diseases.¹⁻⁴



1. Annala, A.; Ilochonwu, B. C.; Wilbie, D.; Sadeghi, A.; Hennink, W. E.; Vermonden, T., Self-Healing Thermosensitive Hydrogel for Sustained Release of Dexamethasone for Ocular Therapy. *ACS Polym Au* **2023**, 3 (1), 118-131.
2. Ilochonwu, B. C.; Urtti, A.; Hennink, W. E.; Vermonden, T., Intravitreal hydrogels for sustained release of therapeutic proteins. *J Control Release* **2020**, 326, 419-441.
3. Ilochonwu, B. C.; van der Lugt, S. A.; Annala, A.; Di Marco, G.; Sampon, T.; Siepmann, J.; Siepmann, F.; Hennink, W. E.; Vermonden, T., Thermo-responsive Diels-Alder stabilized hydrogels for ocular drug delivery of a corticosteroid and an anti-VEGF fab fragment. *J Control Release* **2023**, 361, 334-349.
4. Ilochonwu, B. C.; Mihajlovic, M.; Maas-Bakker, R. F.; Rousou, C.; Tang, M.; Chen, M.; Hennink, W. E.; Vermonden, T., Hyaluronic Acid-PEG-Based Diels-Alder In Situ Forming Hydrogels for Sustained Intraocular Delivery of Bevacizumab. *Biomacromolecules* **2022**, 23 (7), 2914-2929.